journal article·2026-03Open access

NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, Wei Jiang, Bin Liu

Advanced Science· Volume 13· Issue 18

Abstract

Abstract Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy. To address these challenges, this study designs a thermo‐responsive hydrogel (PNH) that encapsulates chitosan (CS)‐coated Fe/Mn bimetallic nanozymes (FMCC) together with cholesterol oxidase (ChOx). FMCC displays multiple enzyme‐mimicking activities, including peroxidase (POD), catalase (CAT), and glutathione oxidase (GSHox). ChOx amplifies this catalytic cascade, enhancing reactive oxygen species (ROS) production and inducing ferroptosis‐mediated tumor cell death. The CS coating improves mucosal adhesion and tissue permeability, thereby facilitating intravesical delivery. Upon near‐infrared (NIR) irradiation, FMCC generates heat that liquefies the hydrogel, enabling spatiotemporally controlled drug release and providing mild photothermal therapy (MPTT). This photothermal effect acts synergistically with ferroptosis induction and immune modulation, concurrently minimizing damage to normal tissues. In parallel, ChOx disrupts cholesterol‐rich membrane rafts and promotes pro‐inflammatory M1 macrophage polarization. Released Mn 2+ ions further potentiate immune activation by stimulating the cGAS–STING pathway, driving IFN‐β and IL‐6 secretion, dendritic cell maturation, and T cell infiltration. Together, this nanozyme–hydrogel system integrates tissue penetration, metabolic disruption, and immune stimulation, representing a promising strategy for localized bladder cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ferroptosis and cancer prognosis · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology China‐Japan Union Hospital of Jilin University Changchun Jilin 130033 China

Department of Dermatology China‐Japan Union Hospital of Jilin University Changchun Jilin 130033 China

Department of Otolaryngology Second Hospital of Jilin University Changchun Jilin 130041 China

CAS Engineering Laboratory for Nanozyme Key Laboratory of Biomacromolecules (CAS) CAS Center for Excellence in Biomacromolecules Institute of Biophysics Chinese Academy of Sciences Beijing 100101 China

Department of Cardiology China‐Japan Union Hospital of Jilin University Changchun Jilin 130033 China

State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer Tianjian Laboratory of Advanced Biomedical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China

Funding

National Natural Science Foundation of China

References (35)

Show source-provided references
1. 10.1038/s41572-023-00468-910.1038/s41572-023-00468-9 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1016/j.eururo.2019.08.01610.1016/j.eururo.2019.08.016 ↗
4. 10.1038/s41385-022-00565-010.1038/s41385-022-00565-0 ↗
5. 10.1001/jama.2020.1759810.1001/jama.2020.17598 ↗
6. 10.1002/adma.20250245210.1002/adma.202502452 ↗
7. 10.1158/1557-3265.BLADDER19-A0910.1158/1557-3265.BLADDER19-A09 ↗
8. 10.1186/s12957-022-02786-w10.1186/s12957-022-02786-w ↗
9. 10.1002/adma.20230926110.1002/adma.202309261 ↗
10. 10.1021/acsnano.4c1308710.1021/acsnano.4c13087 ↗
11. 10.1080/17425247.2020.181001610.1080/17425247.2020.1810016 ↗
12. 10.1002/smll.20190093610.1002/smll.201900936 ↗
13. 10.2147/IJN.S50542710.2147/IJN.S505427 ↗
14. 10.1016/j.jconrel.2014.04.03310.1016/j.jconrel.2014.04.033 ↗
15. 10.1158/0008-5472.CAN-12-456110.1158/0008-5472.CAN-12-4561 ↗
16. 10.1016/j.bioactmat.2025.06.00410.1016/j.bioactmat.2025.06.004 ↗
17. 10.1021/acsnano.3c0417510.1021/acsnano.3c04175 ↗
18. 10.3390/pharmaceutics1209085910.3390/pharmaceutics12090859 ↗
19. 10.1002/adfm.20230919110.1002/adfm.202309191 ↗
20. 10.1038/s41392-024-02088-510.1038/s41392-024-02088-5 ↗
21. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
22. 10.1016/j.cmet.2020.10.01110.1016/j.cmet.2020.10.011 ↗
23. 10.1016/j.bbcan.2020.18835110.1016/j.bbcan.2020.188351 ↗
24. 10.1038/s43018-024-00849-310.1038/s43018-024-00849-3 ↗
25. 10.1016/j.cmet.2019.04.00210.1016/j.cmet.2019.04.002 ↗
26. 10.1158/0008-5472.CAN-23-370310.1158/0008-5472.CAN-23-3703 ↗
27. 10.1016/j.celrep.2023.11234510.1016/j.celrep.2023.112345 ↗
28. 10.1016/j.ccell.2023.02.01610.1016/j.ccell.2023.02.016 ↗
29. 10.1186/s13045-025-01691-510.1186/s13045-025-01691-5 ↗
30. Wang L. · Science · 2019 · 365 · 656
31. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
32. 10.1016/j.ijbiomac.2024.13453110.1016/j.ijbiomac.2024.134531 ↗
33. 10.2147/IJN.S40502010.2147/IJN.S405020 ↗
34. 10.1002/adma.20210599910.1002/adma.202105999 ↗
35. 10.1016/j.pmatsci.2020.10070210.1016/j.pmatsci.2020.100702 ↗